Interpretable machine learning framework for peptide lead optimization in ultralarge design spaces

Abstract In modern peptide drug discovery, the incorporation of noncanonical amino acids (ncAAs) has become a powerful strategy to improve potency and key developability properties, including stability, solubility, and oral bioavailability. This shift has expanded peptide chemical diversity and design spaces well beyond natural residues, creating fundamental challenges for predictive methods (e.g., quantitative structure-activity relationship modeling) used in lead optimization: limited transferability from natural residues to novel ncAAs, limited interpretability, and poor scalability to ultralarge peptide spaces (>10 50 ). We present PepOpt, an interpretable machine learning framework that unifies molecule-based and sequence-based peptide representations in linear models and exploits dynamic programming to efficiently explore ultralarge peptide spaces. PepOpt achieves high predictive accuracy and interpretability, supports training and inference across diverse ncAAs, including ncAAs absent from the training set whose constituent substructures are represented in the training data. Its linear structure decomposes predictions into residue-specific contributions, enabling systematic optimization without exhaustive sequence enumeration. Notably, PepOpt is inherently capable of multi-parameter optimization without specialized modifications. Together, these capabilities position PepOpt as a valuable platform for prediction, interpretation, ideation, and rapid exploration in ncAA-rich ultralarge peptide chemical spaces, accelerating the rational design of novel peptide therapeutics.

Authors

Institutions

Publication Details

Journal
npj Drug Discovery.
Published
2026-10-12
DOI
https://doi.org/10.1038/s44386-026-00069-y
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interpretable machine learning framework for peptide lead optimization in ultralarge design spaces

Dan Sindhikara, Yixiang Mao, Shasha Feng, Amy Bittner McCracken et al.
npj Drug Discovery.
Computational Drug Discovery Methods
article

Interpretable machine learning framework for peptide lead optimization in ultralarge design spaces

Dan Sindhikara, Yixiang Mao, Shasha Feng, Amy Bittner McCracken, Bryant Kim, Jennifer M. Johnston, Dipannita Kalyani, Tianxiong Mi, Robert P. Sheridan, Christopher W. Plummer, Ruibo Zhang, Liying Zhang, Li Xiao
article en

Abstract

Abstract In modern peptide drug discovery, the incorporation of noncanonical amino acids (ncAAs) has become a powerful strategy to improve potency and key developability properties, including stability, solubility, and oral bioavailability. This shift has expanded peptide chemical diversity and design spaces well beyond natural residues, creating fundamental challenges for predictive methods (e.g., quantitative structure-activity relationship modeling) used in lead optimization: limited transferability from natural residues to novel ncAAs, limited interpretability, and poor scalability to ultralarge peptide spaces (>10 50 ). We present PepOpt, an interpretable machine learning framework that unifies molecule-based and sequence-based peptide representations in linear models and exploits dynamic programming to efficiently explore ultralarge peptide spaces. PepOpt achieves high predictive accuracy and interpretability, supports training and inference across diverse ncAAs, including ncAAs absent from the training set whose constituent substructures are represented in the training data. Its linear structure decomposes predictions into residue-specific contributions, enabling systematic optimization without exhaustive sequence enumeration. Notably, PepOpt is inherently capable of multi-parameter optimization without specialized modifications. Together, these capabilities position PepOpt as a valuable platform for prediction, interpretation, ideation, and rapid exploration in ncAA-rich ultralarge peptide chemical spaces, accelerating the rational design of novel peptide therapeutics.

npj Drug Discovery.Vol. 3(1)
Texas Tech University (US), Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Openalex Percentile: Top 13%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.